Skip to main content
Premium Trial:

Request an Annual Quote

SeraCare Life Sciences Seraseq Solid Tumor Mutation Mix

SeraCare Life Sciences' precision medicine unit has launched its first product, Seraseq Solid Tumor Mutation Mix – I(AF20), a biosynthetic reference material designed to evaluate the performance of next-generation sequencing-based tumor profiling assays. The research-use-only product contains a mixture of mutations in key oncogenes and tumor suppressor genes and is intended as a quality material for translational and disease research testing, SeraCare said. It also allows laboratories to monitor library preparation, sequencing, and variant allele detection under a given set of bioinformatics parameters.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.